Trial Profile
A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Imatinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2008 Status changed from completed to in progress according to ClinicalTrials.gov.
- 01 Apr 2008 Status changed from recruiting to completed, according to clinicaltrials.gov record.